AMAG Pharma (AMAG) Misses Q3 EPS by 16c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
AMAG Pharmaceuticals Reports Third Quarter 2015 Financial Results
November 3, 2015 7:30 AM ESTAchieves non-GAAP quarterly revenue of $103.5 million and adjusted EBITDA of $52.8 million
Provides new updates on Makena next generation development programs
Closes acquisition and initiates integration of Cord Blood Registry
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the third quarter and year-to-date periods ended September 30, 2015. Total revenues for the third quarter of 2015 increased to $96.2 million, compared with $25.5 million in the third... More
AMAG Pharmaceuticals Reports Third Quarter 2015 Financial Results
November 3, 2015 7:30 AM ESTAchieves non-GAAP quarterly revenue of $103.5 million and adjusted EBITDA of $52.8 million
Provides new updates on Makena next generation development programs
Closes acquisition and initiates integration of Cord Blood Registry
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the third quarter and year-to-date periods ended September 30, 2015. Total revenues for the third quarter of 2015 increased to $96.2 million, compared with $25.5 million in the third... More
